Welcome to our dedicated page for Enovis SEC filings (Ticker: ENOV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Enovis Corporation (NYSE: ENOV) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Enovis describes itself as an innovation-driven medical technology growth company with two primary segments, Prevention & Recovery (P&R) and Reconstructive (Recon), and its filings offer detailed insight into how this orthopedic-focused business reports its financial condition, capital structure and governance matters.
Investors can review Form 8-K filings where Enovis reports material events, such as quarterly earnings releases, changes in senior leadership roles, amendments to its credit agreement and other significant corporate developments. For example, recent 8-Ks have covered second- and third-quarter financial results, a retirement transition for a senior human resources executive, and an amendment to the company’s credit agreement that adjusts maturity dates, leverage ratio thresholds and borrowing terms.
Beyond current reports, Enovis’ annual reports on Form 10-K and quarterly reports on Form 10-Q (accessible via EDGAR) typically contain segment information for Prevention & Recovery and Reconstructive, discussions of non-GAAP measures such as adjusted EBITDA and adjusted net income, and risk factor disclosures that may reference acquisitions and integration, including the acquisition of Lima. These filings help explain how the company evaluates its performance and manages its medical technology portfolio.
Stock Titan enhances access to Enovis filings by pairing real-time updates from EDGAR with AI-powered summaries that explain the key points in plain language. Users can quickly understand what a new 8-K, 10-Q or 10-K means for Enovis’ operations, capital structure or governance without reading every page. The platform also makes it easier to track items such as credit agreement amendments and other direct financial obligations that Enovis reports under the SEC’s requirements.
Enovis CORP senior vice president and chief HR officer Patricia A. Lang reported a tax-related share disposition through net settlement of restricted stock units. The company withheld 1,173 shares of common stock at $25.79 per share to cover tax withholding and remittance obligations, and the filing states this does not represent a sale by Lang. After this withholding, she directly holds 53,086 shares of Enovis common stock.
Enovis CORP Chief Administrative Officer Oliver Engert reported buying 1,250 shares of common stock in open-market transactions. He purchased 1,000 shares at a weighted average price of $24.77 on March 3, 2026, and 250 shares at $25.10 on March 4, 2026, bringing his direct holdings to 44,890 shares.
The filing notes that the $24.77 price reflects a weighted average for multiple trades completed between $24.64 and $24.89 per share.
Enovis CORP senior executive reports routine tax-share withholding. SVP and Chief Legal Officer Bradley J. Tandy had 484 shares of common stock, at a price of $25.47 per share, withheld by the company to cover tax obligations from restricted stock units. After this non‑market tax-withholding disposition, he holds 43,031 shares directly.
Enovis CORP senior vice president and chief human resources officer Patricia A. Lang reported a tax-related share disposition. On this Form 4, the company withheld 497 shares of common stock at $25.47 per share to cover tax obligations tied to restricted stock units, and the footnote clarifies this does not represent a sale by her. After this withholding, she directly owned 54,259 shares of Enovis common stock.
Enovis CORP executive Louis Vogt reported a small tax-related share disposition. On this Form 4, the company withheld 889 shares of common stock at $25.47 per share to cover tax obligations tied to restricted stock units. This withholding is not an open-market sale, and Vogt continues to hold 35,496 shares directly.
Enovis Corp executive reports tax-related share withholding. Group President, P&R Terry D. Ross had 418 shares of Enovis common stock withheld at $25.47 per share to cover tax obligations from restricted stock units. This administrative transaction, described as not representing a sale, leaves Ross holding 35,371 shares directly.
Enovis Corp's Chief Administrative Officer buys additional shares. Oliver Engert purchased 1,000 shares of Enovis common stock in an open-market transaction at a price of $25.50 per share. Following this purchase, he directly owns 43,640 shares of Enovis common stock.
Enovis CORP director Shirley Brady reported a Form 4 transaction involving 1,492 shares of common stock on February 28, 2026. The shares were withheld by the company at $25.47 per share to cover tax obligations tied to the net settlement of restricted stock units and, according to the disclosure, do not represent a sale by Brady. After this tax-withholding event, Brady’s directly held ownership stood at 104,302 shares of Enovis common stock.
Enovis Corp principal accounting officer John Kleckner reported a tax-withholding share disposition related to restricted stock units. The company withheld 315 shares of common stock at $25.47 per share to satisfy tax obligations, which the footnote clarifies does not represent a sale by Kleckner. After this adjustment, he directly holds 11,987 Enovis shares.
Enovis Corp Senior Vice President and Chief Financial Officer Phillip Benjamin (Ben) Berry reported a tax-related share withholding. On February 28, 2026, 720 shares of common stock at $25.47 per share were withheld by the company to cover tax obligations, leaving him with 116,009 directly owned shares. The filing states this withholding does not represent an open-market sale by Berry.